Optimising dry powder inhaler programmes through formulation

The use of dry powder formulations originally focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) because pulmonary administration of the active pharmaceutical ingredient (API) provides direct and rapid action. However, delivery to the lung is also a quick and efficient way of administering non-respiratory drugs systemically without having to wait for them to be absorbed through the gut.